61 – 70 of 165
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Immunohistochemistry subtyping of urothelial carcinoma is feasible in the daily practice
(
- Contribution to journal › Article
-
Mark
Robot-assisted nephroureterectomy for upper tract urothelial carcinoma—feasibility and complications : a single center experience
(
- Contribution to journal › Article
-
Mark
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
(
- Contribution to journal › Letter
-
Mark
Molecular pathology of the non-luminal Ba/Sq-like and Sc/NE-like classes of urothelial tumours : An integrated immunohistochemical analysis
(
- Contribution to journal › Article
-
Mark
Interaction between blood pressure and genetic risk score for bladder cancer, and risk of urothelial carcinoma in men
(
- Contribution to journal › Article
-
Mark
The Urothelial Transcriptomic Response to Interferon Gamma : Implications for Bladder Cancer Prognosis and Immunotherapy
(
- Contribution to journal › Article
-
Mark
Anorectal dysfunction after radical cystectomy for bladder cancer
(
- Contribution to journal › Article
-
Mark
Standardized care pathways for patients with suspected urinary bladder cancer : the Swedish experience
(
- Contribution to journal › Article
-
Mark
Immunohistochemical Assays for Bladder Cancer Molecular Subtyping : Optimizing Parsimony and Performance of Lund Taxonomy Classifiers
(
- Contribution to journal › Article
-
Mark
Bladder cancer recurrence in papillary urothelial neoplasm of low malignant potential (PUNLMP) compared to G1 WHO 1999 : a population-based study
(
- Contribution to journal › Article